Refractory Diffuse Large B-Cell Lymphoma Clinical Trials in New York, New York

4 studies are recruiting for refractory diffuse large b-cell lymphoma in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

    This phase I trial tests the safety, side effects, and best dose of nivolumab in combination with ASTX727 in treating B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
    Locations
    9 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT05272384 on ClinicalTrials.gov

  2. Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

    This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or not responded to treatment (refractory)…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    7 in total
    Run by
    AIDS Malignancy Consortium

    See if you can join NCT05077527 on ClinicalTrials.gov

  3. Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

    This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
    Locations
    87 in total
    Run by
    SWOG Cancer Research Network

    See if you can join NCT05633615 on ClinicalTrials.gov

  4. Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

    This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or did not respond to earlier treatment. Tazemetosta…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
    Locations
    104 in total
    Run by
    SWOG Cancer Research Network

    See if you can join NCT05890352 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.